PROMISS Diagnostics develops a non-invasive diagnostic test specifically for ovarian cancer detection. This technology aims to provide clinicians with a precise tool for identifying the disease at early stages when survival rates are highest. The company focuses on improving patient outcomes while addressing the unmet need for accessible and efficacious ovarian cancer screening.
Funding
$400K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
WAFounders
Product
Problem
Ovarian cancer is the deadliest gynecologic cancer, often diagnosed late due to a lack of readily available and accurate diagnostic tools. The current standard of care often leads to late-stage diagnosis, resulting in significantly lower survival rates. Distinguishing between benign and malignant pelvic masses at an early stage remains a significant clinical challenge.
Solution
PROMISS Diagnostics is developing PROMISS (Predicting Risk of Ovarian Malignancy In Serum Samples), a non-invasive, machine-learning-based diagnostic test for the early detection of ovarian cancer. The test utilizes a proprietary algorithm that analyzes well-characterized, objective parameters from serum samples to generate a concise risk score. This score helps clinicians differentiate between benign and malignant adnexal masses, enabling earlier diagnosis and potentially improving patient outcomes. The PROMISS test leverages existing immunoassay equipment, making it a scalable and cost-effective solution for widespread use.
Target Audience
The primary target audience includes clinicians, particularly gynecologists and oncologists, who require improved diagnostic tools for early and accurate detection of ovarian cancer in women presenting with adnexal masses.
Features
- Proprietary machine-learning algorithm for analyzing serum parameters
- Non-invasive blood-based test
- Provides a concise risk score indicating the likelihood of ovarian cancer
- Utilizes readily available and objective parameters
- Compatible with existing standard immunochemistry systems
- High sensitivity and specificity compared to the standard of care (CA125, U/S)
- Potential applications in diagnostic aid, monitoring, and screening for ovarian cancer